Nichi-Iko Secures Up To ¥98.5bn Debt Relief As ADR Pushes Ahead
Company Is Set To Delist From Tokyo Stock Exchange Later This Year
Troubled Japanese firm Nichi-Iko has currently has ¥55.8bn of debt forgiveness, which may expand to ¥98.5bn in the future. It currently faces regular payments until 2033 to settle all of its debts.
You may also be interested in...
Down But Not Out: Nichi-Iko Hives Off Sagent, Exits North America
Seven years after it paid almost three quarters of a billion dollars for US-based Sagent, troubled Nichi-Iko is offloading the struggling business.
What’s Next? Five Things To Look Out For In March
Prepare for all the biggest industry actions and events in March 2023 with Generics Bulletin’s monthly column.
Nichi-Iko Set To Delist In March As Tamura Steps Down As CEO
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.